GSK plc (NYSE:GSK) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC reduced its stake in shares of GSK plc (NYSE:GSK - Free Report) by 24.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,806 shares of the pharmaceutical company's stock after selling 7,509 shares during the period. Yousif Capital Management LLC's holdings in GSK were worth $805,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in GSK. FMR LLC raised its stake in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its holdings in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after buying an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC raised its position in shares of GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company's stock valued at $16,747,000 after buying an additional 51,378 shares during the period. Cerity Partners LLC grew its position in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company's stock worth $17,728,000 after acquiring an additional 165,556 shares during the period. Finally, Natixis Advisors LLC increased its stake in GSK by 20.0% during the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company's stock worth $20,460,000 after acquiring an additional 83,433 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of NYSE:GSK traded down $0.08 during trading on Wednesday, reaching $36.54. The company had a trading volume of 3,167,881 shares, compared to its average volume of 4,563,176. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The firm has a market capitalization of $75.72 billion, a price-to-earnings ratio of 22.98, a price-to-earnings-growth ratio of 1.11 and a beta of 0.64. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock's fifty day moving average price is $34.45 and its 200 day moving average price is $37.39.

GSK (NYSE:GSK - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities research analysts predict that GSK plc will post 4.12 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.3932 per share. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a yield of 4.30%. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's payout ratio is currently 93.08%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GSK. Deutsche Bank Aktiengesellschaft cut shares of GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. StockNews.com upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Guggenheim lowered GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Finally, Jefferies Financial Group lowered GSK from a "buy" rating to a "hold" rating and lowered their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven research analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.